CN106211770B - 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮 - Google Patents
作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮 Download PDFInfo
- Publication number
- CN106211770B CN106211770B CN201580018466.7A CN201580018466A CN106211770B CN 106211770 B CN106211770 B CN 106211770B CN 201580018466 A CN201580018466 A CN 201580018466A CN 106211770 B CN106211770 B CN 106211770B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- alkoxy
- halo
- cycloalkyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C12c3ccccc3*CC1C2 Chemical compound *C12c3ccccc3*CC1C2 0.000 description 6
- YMOODPYYBAKOPT-UHFFFAOYSA-N CC(C)(C=C(C=O)c1c2)Oc1ccc2OC(F)(F)F Chemical compound CC(C)(C=C(C=O)c1c2)Oc1ccc2OC(F)(F)F YMOODPYYBAKOPT-UHFFFAOYSA-N 0.000 description 1
- CBVLFBDYGYZIIC-UHFFFAOYSA-N CC1(C)Oc(ccc(OC(F)(F)F)c2)c2C(CO)=C1 Chemical compound CC1(C)Oc(ccc(OC(F)(F)F)c2)c2C(CO)=C1 CBVLFBDYGYZIIC-UHFFFAOYSA-N 0.000 description 1
- AKXHMIAUQBGELM-UHFFFAOYSA-N CC1(CC1)c1ccc2OCC(C3)C3(CO)c2c1 Chemical compound CC1(CC1)c1ccc2OCC(C3)C3(CO)c2c1 AKXHMIAUQBGELM-UHFFFAOYSA-N 0.000 description 1
- WRAOEPAKEUJWCV-QPNGRYJLSA-N CC1(CC1)c1ccc2OCC(C3)[C@]3(CN(CCN(C3CC=C4[n]5cnc(C)c5)C4=[U])C3=O)c2c1 Chemical compound CC1(CC1)c1ccc2OCC(C3)[C@]3(CN(CCN(C3CC=C4[n]5cnc(C)c5)C4=[U])C3=O)c2c1 WRAOEPAKEUJWCV-QPNGRYJLSA-N 0.000 description 1
- RZUZDLMJRVAETO-UHFFFAOYSA-N CCC(C(C)C1)C(C)=CN1C1=CCC(C(O)=O)NC1=O Chemical compound CCC(C(C)C1)C(C)=CN1C1=CCC(C(O)=O)NC1=O RZUZDLMJRVAETO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461973436P | 2014-04-01 | 2014-04-01 | |
| US61/973,436 | 2014-04-01 | ||
| PCT/IB2015/051988 WO2015150957A1 (en) | 2014-04-01 | 2015-03-18 | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106211770A CN106211770A (zh) | 2016-12-07 |
| CN106211770B true CN106211770B (zh) | 2018-02-06 |
Family
ID=52815058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580018466.7A Expired - Fee Related CN106211770B (zh) | 2014-04-01 | 2015-03-18 | 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150274721A1 (enExample) |
| EP (1) | EP3126361B1 (enExample) |
| JP (1) | JP6643247B2 (enExample) |
| KR (1) | KR101886945B1 (enExample) |
| CN (1) | CN106211770B (enExample) |
| AP (1) | AP2016009465A0 (enExample) |
| AR (1) | AR099874A1 (enExample) |
| AU (1) | AU2015242330B2 (enExample) |
| BR (1) | BR112016022519A8 (enExample) |
| CA (1) | CA2944308A1 (enExample) |
| CL (1) | CL2016002422A1 (enExample) |
| CR (1) | CR20160454A (enExample) |
| CU (1) | CU20160140A7 (enExample) |
| DK (1) | DK3126361T3 (enExample) |
| DO (1) | DOP2016000266A (enExample) |
| EA (1) | EA031419B1 (enExample) |
| EC (1) | ECSP16078289A (enExample) |
| ES (1) | ES2759277T3 (enExample) |
| IL (1) | IL248154B (enExample) |
| MD (1) | MD20160102A2 (enExample) |
| MX (1) | MX369074B (enExample) |
| NI (1) | NI201600149A (enExample) |
| PE (1) | PE20161364A1 (enExample) |
| PH (1) | PH12016501864A1 (enExample) |
| SG (1) | SG11201607465UA (enExample) |
| TW (1) | TWI568733B (enExample) |
| UY (1) | UY36054A (enExample) |
| WO (1) | WO2015150957A1 (enExample) |
| ZA (1) | ZA201606252B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2016125048A1 (en) * | 2015-02-03 | 2016-08-11 | Pfizer Inc. | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| CN106580997B (zh) * | 2016-12-09 | 2018-01-19 | 张田 | 一种治疗先兆流产的药物组合物 |
| KR20190098998A (ko) | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
| TWI838401B (zh) | 2018-09-12 | 2024-04-11 | 瑞士商諾華公司 | 抗病毒性吡啶并吡𠯤二酮化合物 |
| CN110907542A (zh) * | 2018-09-17 | 2020-03-24 | 复旦大学 | 一种液质联用检测唾液中司来吉兰及其代谢物的方法 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| WO2020179859A1 (ja) | 2019-03-06 | 2020-09-10 | 第一三共株式会社 | ピロロピラゾール誘導体 |
| TWI867053B (zh) | 2019-09-26 | 2024-12-21 | 瑞士商諾華公司 | 抗病毒吡唑并吡啶酮化合物 |
| WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
| WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012131539A1 (en) * | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| WO2013171712A1 (en) * | 2012-05-16 | 2013-11-21 | Janssen Pharmaceuticals, Inc. | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease |
| CN104936958A (zh) * | 2013-01-17 | 2015-09-23 | 詹森药业有限公司 | 作为γ分泌酶调节剂的新颖的经取代的吡啶并-哌嗪酮衍生物 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017197A1 (fr) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| NZ337765A (en) | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| SI1257584T2 (sl) | 2000-02-24 | 2013-07-31 | Washington University St. Louis | Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| CA2427661C (en) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| ES2250883T3 (es) * | 2002-02-28 | 2006-04-16 | Sanofi-Aventis | Derivados de 2-piridinil y 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona sustituidos con heteroarilo. |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| BR0315157A (pt) | 2002-10-09 | 2005-08-09 | Rinat Neuroscience Corp | Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| EP1638935A1 (en) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonist |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| BRPI0507374A (pt) | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
| MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| US7812040B2 (en) | 2005-06-22 | 2010-10-12 | Pfizer Inc. | Histamine-3 receptor antagonists |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| WO2007052124A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| WO2007105053A2 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| HRP20110539T1 (hr) | 2006-04-21 | 2011-08-31 | Pfizer Products Inc. | PIRIDINO[3,4-b]PIRAZINONI |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| CA2676456C (en) | 2007-01-22 | 2012-03-27 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| AU2009307892A1 (en) * | 2008-10-23 | 2010-04-29 | Merck Sharp & Dohme Corp. | Fused heterocyclic M1 receptor positive allosteric modulators |
| UA110688C2 (uk) * | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2015049616A1 (en) * | 2013-10-04 | 2015-04-09 | Pfizer Inc. | Novel bicyclic pyridinones as gamma-secretase modulators |
-
2015
- 2015-03-18 WO PCT/IB2015/051988 patent/WO2015150957A1/en not_active Ceased
- 2015-03-18 CN CN201580018466.7A patent/CN106211770B/zh not_active Expired - Fee Related
- 2015-03-18 CR CR20160454A patent/CR20160454A/es unknown
- 2015-03-18 ES ES15714951T patent/ES2759277T3/es active Active
- 2015-03-18 DK DK15714951.9T patent/DK3126361T3/da active
- 2015-03-18 MX MX2016012904A patent/MX369074B/es active IP Right Grant
- 2015-03-18 AU AU2015242330A patent/AU2015242330B2/en not_active Ceased
- 2015-03-18 AP AP2016009465A patent/AP2016009465A0/en unknown
- 2015-03-18 SG SG11201607465UA patent/SG11201607465UA/en unknown
- 2015-03-18 MD MDA20160102A patent/MD20160102A2/ro not_active Application Discontinuation
- 2015-03-18 EP EP15714951.9A patent/EP3126361B1/en active Active
- 2015-03-18 PE PE2016001895A patent/PE20161364A1/es not_active Application Discontinuation
- 2015-03-18 CA CA2944308A patent/CA2944308A1/en not_active Withdrawn
- 2015-03-18 EA EA201600619A patent/EA031419B1/ru not_active IP Right Cessation
- 2015-03-18 KR KR1020167030135A patent/KR101886945B1/ko not_active Expired - Fee Related
- 2015-03-18 BR BR112016022519A patent/BR112016022519A8/pt not_active IP Right Cessation
- 2015-03-18 JP JP2016559879A patent/JP6643247B2/ja not_active Expired - Fee Related
- 2015-03-27 AR ARP150100922A patent/AR099874A1/es unknown
- 2015-03-27 US US14/670,746 patent/US20150274721A1/en not_active Abandoned
- 2015-03-27 UY UY0001036054A patent/UY36054A/es not_active Application Discontinuation
- 2015-03-31 TW TW104110551A patent/TWI568733B/zh not_active IP Right Cessation
-
2016
- 2016-09-09 ZA ZA2016/06252A patent/ZA201606252B/en unknown
- 2016-09-22 CU CUP2016000140A patent/CU20160140A7/es unknown
- 2016-09-22 PH PH12016501864A patent/PH12016501864A1/en unknown
- 2016-09-27 CL CL2016002422A patent/CL2016002422A1/es unknown
- 2016-09-29 NI NI201600149A patent/NI201600149A/es unknown
- 2016-09-29 DO DO2016000266A patent/DOP2016000266A/es unknown
- 2016-09-29 IL IL248154A patent/IL248154B/en active IP Right Grant
- 2016-09-30 EC ECIEPI201678289A patent/ECSP16078289A/es unknown
-
2017
- 2017-02-24 US US15/441,882 patent/US20170166566A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012131539A1 (en) * | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| WO2013171712A1 (en) * | 2012-05-16 | 2013-11-21 | Janssen Pharmaceuticals, Inc. | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease |
| CN104936958A (zh) * | 2013-01-17 | 2015-09-23 | 詹森药业有限公司 | 作为γ分泌酶调节剂的新颖的经取代的吡啶并-哌嗪酮衍生物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106211770B (zh) | 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮 | |
| CN110944998B (zh) | 二氢-吡咯并-吡啶衍生物 | |
| CN104662021B (zh) | 新的双环吡啶酮类 | |
| CN106795165A (zh) | 咪唑并哒嗪化合物 | |
| TWI616445B (zh) | 新穎環丙苯并呋喃基吡啶并吡二酮類 | |
| CA2925743C (en) | Novel bicyclic pyridinones as gamma-secretase modulators | |
| HK1231481B (zh) | 作为γ-分泌酶调节剂的色烯和1，1A，2，7B-四氢环丙烷并[C]色烯吡啶并吡嗪二酮 | |
| US20160229847A1 (en) | Novel bicyclic pyridinones as gamma-secretase modulators | |
| HK1242315B (zh) | 新颖环丙苯并呋喃基吡啶并吡嗪二酮类 | |
| OA18058A (en) | Chromene and 1,1 A,2,7B-tetrahydrocyclopropa[C]chromene pyridopyrazinediones as gamma-secretase modulators. | |
| HK1242315A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| HK1237335B (zh) | 咪唑并哒嗪化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1231481 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180206 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |